Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND
Stacy Rudnicki, M.D., Vice President, Clinical Research, Cytokinetics, presented an analysis of the baseline characteristics of the first 27 patients enrolled in COURAGE-ALS.
- Stacy Rudnicki, M.D., Vice President, Clinical Research, Cytokinetics, presented an analysis of the baseline characteristics of the first 27 patients enrolled in COURAGE-ALS.
- COURAGE-ALS is a Phase 3, multi-center, double-blind, randomized, placebo-controlled trial of reldesemtiv expected to enroll approximately 555 patients with ALS.
- Key inclusion criteria in COURAGE-ALS include symptom onset within 24 months and ALS Functional Rating Scale-Revised (ALSFRS-R) total score of 44.
- For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission.